WO1999018131A2 - Anti-bip-antikörper bei rheumatoider arthritis sowie verfahren und testkits zu ihrer bestimmung - Google Patents
Anti-bip-antikörper bei rheumatoider arthritis sowie verfahren und testkits zu ihrer bestimmung Download PDFInfo
- Publication number
- WO1999018131A2 WO1999018131A2 PCT/DE1998/002942 DE9802942W WO9918131A2 WO 1999018131 A2 WO1999018131 A2 WO 1999018131A2 DE 9802942 W DE9802942 W DE 9802942W WO 9918131 A2 WO9918131 A2 WO 9918131A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- bip
- antibodies
- buffer
- ionic
- bound
- Prior art date
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6854—Immunoglobulins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
Definitions
- the invention relates to anti-heavy chain binding protein antibodies (anti-BiP antibodies) and to methods and test kits for determining anti-heavy chain binding protein (anti-Grp78) antibodies in body fluids. It relates in particular to the detection of these antibodies as autoantibodies for the serological diagnosis of rheumatoid arthritis in differential diagnosis to other diseases of the rheumatic type in vitro.
- Rheumatoid arthritis is the most common inflammatory joint disease, which affects approximately 1-2% of the population. Autoantibodies, especially rheumatoid factors, develop in the course of the disease. Rheumatoid factors have so far been the only serological markers used to diagnose RA. However, they are also detectable in other diseases of the rheumatic type, such as systemic lupus erythematosus, systemic scleroderma and mixed collagen diseases, and even in the healthy population. The specificity of the rheumatoid factor for RA is only 74%, its frequency among RA patients 68% (Bläß St, Specker Ch, Lakomek HJ, Schneider EM, Schwochau M.
- RA rheumatoid arth ⁇ tis
- BiP Heavy Chain Binding Protein
- Glucose Regulated Protein 78 is a so-called molecular chaperone that occurs in the endoplasmic reticulum and is responsible for the folding and complexation of proteins that take the secretory path. It belongs to the Hsp70 family of stress proteins and is an ubiquitously expressed, highly conserved protein that is essential in yeast. BiP was so far not associated with rheumatoid arthritis. This may be due to the fact that the anti-BiP antibodies are directed against a glycosidic epitope which is not expressed in the expression systems used hitherto.
- the invention has for its object to provide anti-heavy chain binding protein antibodies from patients with rheumatoid arthritis, a safe method for
- anti-BiP antibodies were obtained by binding natural (biochemically purified) or recombinant BiP to a solid phase and using them to enrich the antibodies from body fluids.
- the antibodies are detached from the antigen-antibody complex with the aid of chaotropic substances.
- BiP is natural (biochemically purified) or recombinantly on solid
- the antigen in its glycosylated form is particularly preferred.
- Body fluids consist of binding the protein BiP to solid phases and in the
- BiP is adsorptively or covalently bound to solid phases, if necessary after prior chemical activation of the solid phase.
- Antigen is used natural (biochemically purified) or recombinant BiP.
- the solid phase consists of polystyrene, polyvinylidene fluoride or nitrocellulose in different geometric shapes, such as .Microtitration plates, tubes or in a spherical or sheet-like shape.
- the anti-BiP antibodies are determined bound in the immunoassay.
- the bound anti-BiP antibodies are detected by specific conjugates, which are directed against single immunoglobulin classes or against several.
- the test kit according to the invention for the determination of anti-BiP antibodies is characterized by:
- BiP in purified or recombinant form, which is bound to a solid phase by adsorption or covalently,
- a buffer for the dilution of the biological fluid to be examined which contains non-ionic or ionic detergents or proteins,
- a specific conjugate consisting of an antibody which is directed against human immunoglobulin IgG, IgM, IgA or more of these immunoglobulins and an enzyme or a fluorescent dye or a radioactively labeled component, a buffer for diluting the conjugate, which contains non-ionic or ionic detergents or proteins,
- a buffer for washing (removing) the unbound immunoreactants which contains nonionic or ionic detergents or proteins
- a substrate solution for the detection of the enzyme reaction and
- BiP has an essential function within the cell, a connection between antibody formation and pathogenesis can be established.
- the antibodies according to the invention represent an important finding for differential diagnosis with respect to other diseases of the rheumatic type in which these antibodies do not occur.
- established methods such as enzyme linked immunosorbent assay (ELISA), sandwich ELISA and immunoblot are used in immunology.
- ELISA enzyme linked immunosorbent assay
- sandwich ELISA sandwich ELISA
- immunoblot immunoblot
- the analysis of the antibody reactivities in the ELISA has the advantage in comparison to the immunoblot method, that it saves time and costs. That is why the ELISA is used as a screening method.
- the immunoblot is used. Based on the detection of a serological marker (anti-bip antibody) in patients with rheumatoid arthritis, according to the invention autoantibodies against BiP in patients with rheumatoid arthritis could be detected in 66% of the cases in the ELISA and in the immunoblot.
- Patient sera were tested for auto-reactivity against purified (natural) BiP.
- the anti-BiP antibodies occur with high frequency in RA patients. These antibodies are primarily directed against a glycosidic epitope, the main determinant of which is N-acetylglucosamine.
- BiP was characterized on the basis of its molecular and biochemical properties (relative molecular mass, isoelectric point, amino acid sequence).
- Salts e.g. 3 M guanidinium isothiocyanate solution Wash and concentrate the antibodies
- sample buffer Phosphate Buffered Saline with Nonidet P40, (PBS-NP40), 0.1%, pH 7.0
- sample was applied (serum dilution 1:20 in sample buffer) with 50 ⁇ l / well over 3 hours at room temperature (sample application from patient sera and from control sera from healthy donors and patients of the rheumatic type).
- sample application from patient sera and from control sera from healthy donors and patients of the rheumatic type.
- standard serum was carried out as a calibration curve in 6 linear dilution steps, starting at 1:10.
- the washing process was then carried out three times with washing buffer.
- the measured antibody reactivity of the standard serum at dilution 1:20 was defined as 10,000 relative units (RE).
- the dilution levels 1: 10, 1: 30, 1: 50, 1: 100, 1: 500 correspond to 20000RE, 6667RE, 4000RE.1000RE, 200RE.
- the calibration curve and the serum samples were measured in triplicate. If the antibody reactivity was higher in a serum than in the standard serum, it was measured again at higher dilution levels. The resulting REs were then multiplied by the dilution factor, which was higher than 1: 100.
- Anti-BiP antibodies were detected in the ELISA in 66% of RA patients and in 0.5% of patients with other rheumatic diagnoses, but not in healthy donors.
- HeLa cells were lysed in a buffer containing Gardol, urea and 2-mercaptoethanol and incubated at 70 ° C for 15 min.
- the resulting protein float was taken up in a Lyspuffer which contained the non-ionic detergent NP40 instead of the Gardol and dialyzed against 25mM Tris buffer.
- the material was precipitated with ethanol and separated on a sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) with a 10-20% acrylamide gradient by molecular weight. Gels were electrotransferred onto polyvinylidene fluoride (PVDF).
- PVDF polyvinylidene fluoride
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Hematology (AREA)
- Medicinal Chemistry (AREA)
- Urology & Nephrology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Organic Chemistry (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- Cell Biology (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Peptides Or Proteins (AREA)
Abstract
Description
Claims
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2000514938A JP2001519357A (ja) | 1997-10-01 | 1998-09-30 | 慢性関節リウマチにおける抗BiP抗体並びにそれらの検出のための方法及び試験キット |
EP98958806A EP1019441A2 (de) | 1997-10-01 | 1998-09-30 | Anti-bip-antikörper bei rheumatoider arthritis sowie verfahren und testkits zu ihrer bestimmung |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE1997144132 DE19744132A1 (de) | 1997-10-01 | 1997-10-01 | Anti-Heavy Chain Binding Protein-Antikörper (Anti-BiP-Antikörper) bei rheumatoider Arthritis sowie Verfahren und Testkits zu ihrer Bestimmung in Körperflüssigkeiten |
DE19744132.7 | 1997-10-01 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO1999018131A2 true WO1999018131A2 (de) | 1999-04-15 |
WO1999018131A3 WO1999018131A3 (de) | 1999-06-17 |
Family
ID=7844757
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/DE1998/002942 WO1999018131A2 (de) | 1997-10-01 | 1998-09-30 | Anti-bip-antikörper bei rheumatoider arthritis sowie verfahren und testkits zu ihrer bestimmung |
Country Status (4)
Country | Link |
---|---|
EP (1) | EP1019441A2 (de) |
JP (1) | JP2001519357A (de) |
DE (1) | DE19744132A1 (de) |
WO (1) | WO1999018131A2 (de) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2000021995A1 (en) * | 1998-10-09 | 2000-04-20 | King's College London | Treatment of inflammatory disease |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE10115083A1 (de) * | 2001-03-27 | 2002-10-10 | Schebo Biotech Ag | Nachweis von Milchdrüsenentzündungen |
-
1997
- 1997-10-01 DE DE1997144132 patent/DE19744132A1/de not_active Withdrawn
-
1998
- 1998-09-30 JP JP2000514938A patent/JP2001519357A/ja active Pending
- 1998-09-30 EP EP98958806A patent/EP1019441A2/de not_active Withdrawn
- 1998-09-30 WO PCT/DE1998/002942 patent/WO1999018131A2/de not_active Application Discontinuation
Non-Patent Citations (5)
Title |
---|
CONROY S E ET AL.: "Incidence of anti hsp 90 and 70 antibodies in children with SLE, juvenile dermatomyositis and juvenile chronic arthritis" CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, Bd. 14, Nr. 1, Januar 1996, Seiten 99-104, XP002097731 * |
CRIBB A E ET AL.: "Patients with delayed-onset sulfonamide hypersensitivity reactions have antibodies recognizing endodplasmic reticulum luminal proteins" J.PHARMACOL. EXP. THERAP., Bd. 282 , Nr. 2, August 1997, Seiten 1064-1071, XP002097729 * |
JINDAL S: "Heat shock proteins: applications in health and disease" TRENDS IN BIOTECHNOLOGY, Bd. 14, Nr. 1, Januar 1996, Seite 17-20 XP004035805 * |
MACARIO A J: "Heat - shock proteins and molecular chaperones: implications for pathogenesis, diagnostics, and therapeutics." INTERNATIONAL JOURNAL OF CLINICAL AND LABORATORY RESEARCH, (1995) 25 (2) 59-70. REF: 91 JOURNAL CODE: A81. ISSN: 0940-5437., XP002097732 GERMANY: Germany, Federal Republic of * |
TISHLER M ET AL: "Anti- heat - shock protein antibodies in rheumatic and autoimmune diseases." SEMINARS IN ARTHRITIS AND RHEUMATISM, (1996 OCT) 26 (2) 558-63. REF: 25 JOURNAL CODE: UMV. ISSN: 0049-0172., XP002097730 United States * |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2000021995A1 (en) * | 1998-10-09 | 2000-04-20 | King's College London | Treatment of inflammatory disease |
US6995240B1 (en) | 1998-10-09 | 2006-02-07 | King's College London | Treatment of inflammatory disease |
Also Published As
Publication number | Publication date |
---|---|
DE19744132A1 (de) | 1999-04-22 |
WO1999018131A3 (de) | 1999-06-17 |
EP1019441A2 (de) | 2000-07-19 |
JP2001519357A (ja) | 2001-10-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE19649390A1 (de) | Antigenspezifischer IgG-Nachweis | |
DE2930706A1 (de) | Verfahren zum nachweis von erregerspezifischen antikoerpern | |
DE19649389A1 (de) | Antigenspezifischer IgM-Nachweis | |
JP3630689B2 (ja) | 抗ポリマー抗体の検出方法およびシリコーン関連疾患(srd)の診断を援助するのに有用な診断試験キット | |
EP0008682A1 (de) | Mit einem Proteinmaterial beschichteter Latex, Verfahren zur Herstellung dieses Latex, immunologisches Reagenz enthaltend diesen Latex, Verfahren zur Herstellung dieses Reagenzes, Verwendung dieses Reagenzes, Bestimmungsverfahren unter Verwendung dieses Reagenzes und Reagenziengarnitur enthaltend dieses Reagenz | |
EP0782585B1 (de) | RHEUMAFAKTOR-ENTSTÖRUNG MIT ANTI-Fd-ANTIKÖRPERN | |
DE19651093A1 (de) | Rezeptorbindungsassay zum Nachweis von TSH-Rezeptor-Autoantikörpern sowie Reagenziensatz für die Durchführung eines solchen Rezeptorbindungsassays | |
DE60030701T2 (de) | VERFAHREN ZUM BEWERTEN VON AUTOIMMUNKRANKHEITEN, VERFAHREN ZUM NACHWEIS VON GEGEN Reg GERICHTETEN AUTOANTIKÖRPERN | |
EP1019441A2 (de) | Anti-bip-antikörper bei rheumatoider arthritis sowie verfahren und testkits zu ihrer bestimmung | |
US5529901A (en) | Method for determining the presence or amount of analyte using a stable colloidal carbon sol | |
EP1210602B1 (de) | Verfahren zur diagnose von sjögren-syndrom | |
DE19505266C1 (de) | Verwendung von polyklonalen humanen anti-hTg-Autoantikörpern als Reagenz für die klinische Diagnostik von Schilddrüsen-Autoimmunerkrankungen sowie Reagenziensatz für eine Bestimmung von anti-hTg-Autoantikörpern in Patientenseren | |
US5573911A (en) | Methods and materials for detecting autoimmune antibodies | |
EP0363449B1 (de) | Verfahren zur untersuchung von antikörpern spezifisch für rheumakrankheiten, insbesondere chronische polyarthritis sowie reagens hierfür | |
EP1393076B1 (de) | Verfahren zur vorhersage eines transplantatabstossungsrisikos und immunologischer testkit | |
EP0909954B1 (de) | Nachweis von Knorpelerkrankungen mit MIA | |
EP0453060B1 (de) | Verfahren zur Bestimmung von antinukleären Antikörpern | |
DE19707343C2 (de) | Verfahren zur Bestimmung von Anti-Proteasom-Antikörpern in Körperflüssigkeiten sowie ein Testkit zur Durchführung dieses Verfahrens | |
DE4243375C2 (de) | Bestimmungsverfahren zur Bestimmung von Antikörpern in biologischen Flüssigkeiten | |
EP1476750B1 (de) | Verfahren zur herstellung einer nukleosomen-präparation und deren verwendung zur in vitro-diagnose von systemischem lupus erythemastosus (sle) | |
JP4411438B2 (ja) | アシアロgm1発現細胞検出試薬、これを用いた細胞検出方法および細胞分類方法並びに老化測定方法 | |
EP0488168B1 (de) | Verwendung einer Waschlösung mit Komplexbildner für Metallionen in festphasen-immunometrischen Verfahren | |
WO2009115190A1 (de) | Verfahren zur bestimmung des typs einer entzündlich-rheumatischen erkrankung in synovialflüssigkeit | |
AT395786B (de) | Diagnostisches mittel, insbesondere zur diagnose von chronischer polyarthritis | |
EP0133553A2 (de) | Reagenz und Verfahren zur quantitativen Bestimmung von Antikörpern |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): JP US |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
AK | Designated states |
Kind code of ref document: A3 Designated state(s): JP US |
|
AL | Designated countries for regional patents |
Kind code of ref document: A3 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
WWE | Wipo information: entry into national phase |
Ref document number: 09539894 Country of ref document: US |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1998958806 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 1998958806 Country of ref document: EP |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 1998958806 Country of ref document: EP |